Atrium Therapeutics Launches with $270 Million Focused on RNA Medicines for Genetic Heart Disorders Atrium Therapeutics, newly launched with $270 million, aims to advance RNA therapeutics designed for rare genetic cardiomyopathies. A transformative step for patients.

Atrium Therapeutics Launches with $270 Million Focused on RNA Medicines for Genetic Heart Disorders #USA #San_Diego #Cardiomyopathy #RNA_Medicines #Atrium_Therapeutics